Results 121 to 130 of about 461 (138)

Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3

Journal of Cardiac Failure, 2023
Albree Tower-Rader, Michael A Fifer, Lisa Meng   +2 more
exaly  

Aficamten: First Approval

Drugs
openaire   +1 more source

Aficamten reduces symptoms in obstructive hypertrophic cardiomyopathy

Nature Reviews Cardiology
openaire   +2 more sources

Aficamten and the Future of Obstructive Hypertrophic Cardiomyopathy Management

JACC
openaire   +2 more sources

Aficamten reduces cardiac contractility by modifying the actomyosin interaction

Nature Cardiovascular Research
Farid Moussavi-Harami, Michael Regnier
openaire   +1 more source

Auch Aficamten (Myosininhibitor) hocheffektiv und sicher bei HOCM

Aktuelle Kardiologie, 2023
openaire   +1 more source

Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology
Michael E Nassif, Ian Kulac, Lisa Meng
exaly  

Aficamten for Obstructive Hypertrophic Cardiomyopathy. Reply.

The New England journal of medicine
Martin S, Maron, Caroline J, Coats, Daniel L, Jacoby   +2 more
openaire   +1 more source

Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology
Michael E Nassif, Maria Luisa Peña-Peña, Özlem Bilen   +2 more
exaly  

Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM

Journal of the American College of Cardiology
Michael E Nassif, Anjali Tiku Owens, Albree Tower-Rader   +2 more
exaly